Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a clinical-stage biopharmaceutical company pioneering therapies for rare cancers and viral infections. This dedicated news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.
Access real-time information about Chimerix's innovative pipeline, including its lead candidate dordaviprone for H3 K27M-mutant glioma and ongoing research in antiviral treatments. The curated collection features press releases, financial reports, and scientific presentations – all vital for understanding the company's progress in addressing unmet medical needs.
Key content categories include clinical trial results, FDA communications, partnership announcements, and financial performance updates. Each update is carefully verified to ensure accuracy and relevance for stakeholders monitoring therapeutic advancements in oncology and infectious diseases.
Bookmark this page for streamlined access to Chimerix's latest developments. Check regularly for critical updates on drug approvals, research breakthroughs, and strategic initiatives that shape the company's trajectory in biopharmaceutical innovation.
Chimerix (NASDAQ: CMRX) reported its Q4 and full-year 2024 financial results, highlighting two major developments: the FDA's acceptance of dordaviprone NDA for treating recurrent H3 K27M-mutant diffuse glioma with a PDUFA date of August 18, 2025, and the pending acquisition by Jazz Pharmaceuticals for $8.55 per share ($935 million total).
Financial highlights include:
- Q4 2024 net loss of $23.0 million ($0.25 per share) vs $18.2 million in Q4 2023
- Full-year 2024 net loss of $88.4 million ($0.99 per share) vs $82.1 million in 2023
- Cash position of $140.1 million with no debt
- R&D expenses increased to $17.7 million in Q4 2024
- G&A expenses rose to $7.0 million in Q4 2024
Chimerix (NASDAQ:CMRX) announced that its Compensation Committee granted inducement stock options to a new employee on March 2, 2025. The award consists of non-statutory stock options to purchase up to 70,000 shares of common stock at an exercise price equal to Chimerix's closing trading price on the grant date.
The stock options have a 10-year term with a four-year vesting schedule: 25% vests on the one-year employment anniversary, with the remaining 75% vesting in equal monthly installments over the following three years. While subject to Chimerix's 2024 Equity Incentive Plan terms, these options were granted outside of it.
Chimerix, a biopharmaceutical company, is developing dordaviprone (ONC201) for H3 K27M-mutant glioma and conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.
Jazz Pharmaceuticals has announced the acquisition of Chimerix for $8.55 per share, totaling approximately $935 million in cash. The deal represents a 72% premium based on March 4, 2025 closing price and is expected to close in Q2 2025.
The acquisition centers on dordaviprone, Chimerix's lead clinical asset for treating H3 K27M-mutant diffuse glioma, a rare brain tumor affecting children and young adults. The FDA has granted Priority Review for dordaviprone with a PDUFA date of August 18, 2025. If approved, it could become the first FDA-approved therapy for this condition.
The drug shows promising clinical results and has patent protection until 2037. An ongoing Phase 3 ACTION trial is evaluating dordaviprone in newly diagnosed patients, potentially expanding its use to front-line treatment. The transaction will be funded through Jazz's existing cash and investments.
Jazz Pharmaceuticals (JAZZ) has announced the acquisition of Chimerix for $8.55 per share, representing a total cash consideration of $935 million - a 72% premium over Chimerix's closing price on March 4, 2025. The transaction is expected to close in Q2 2025.
The acquisition centers on dordaviprone, Chimerix's lead clinical asset, a first-in-class treatment for H3 K27M-mutant diffuse glioma, a rare brain tumor affecting children and young adults. The FDA has granted Priority Review for dordaviprone with a PDUFA date of August 18, 2025. If approved, it would be the first FDA-approved therapy specifically for this condition.
The drug is also being evaluated in the ongoing Phase 3 ACTION trial for newly diagnosed patients. Jazz plans to leverage its development and commercial capabilities for a potential launch in the second half of 2025, with patent protection extending to 2037.
Chimerix (NASDAQ:CMRX) has announced the granting of inducement awards to three new employees on February 12, 2025. The awards consist of non-statutory stock options to purchase up to 270,000 shares of Chimerix's common stock, approved by the Compensation Committee of Chimerix's Board of Directors.
The stock options have an exercise price equal to Chimerix's closing trading price on the grant date and a 10-year term. They will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years. While subject to the terms of Chimerix's 2024 Equity Incentive Plan, these grants were made outside of it.
Chimerix is a biopharmaceutical company focused on developing medicines for deadly diseases. Their lead program, dordaviprone (ONC201), is being developed for H3 K27M-mutant glioma, while Phase 1 dose escalation studies of ONC206 are ongoing.
Chimerix (NASDAQ: CMRX) announced FDA acceptance of its New Drug Application (NDA) for dordaviprone, targeting recurrent H3 K27M-mutant diffuse glioma treatment. The application received Priority Review status with a PDUFA target action date of August 18, 2025.
The FDA has not planned an advisory committee meeting for the application review. Dordaviprone has received Rare Pediatric Disease Designation, Fast-Track Designation in the US, and Orphan Drug Designation in the US, Europe, and Australia. The company has applied for a Rare Pediatric Disease Priority Review Voucher in the NDA submission.
If approved, dordaviprone would be the first specific treatment for patients with recurrent H3 K27M-mutant diffuse glioma, a form of high-grade glioma with treatment options beyond palliative care.
Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the upcoming JonesTrading Virtual Precision Medicine Symposium. Mike Andriole, CEO, and Tom Riga, Chief Operating and Commercial Officer, will engage in a fireside chat on Monday, February 3, 2025, at 11:00 a.m. ET.
The presentation will be accessible via audio webcast through the Investor Relations section of Chimerix's website at ir.chimerix.com. The recording will remain available for approximately 90 days following the event.
Chimerix (NASDAQ:CMRX) has announced the granting of inducement awards to six new employees on January 17, 2025. The awards consist of non-statutory stock options to purchase up to 355,000 shares of Chimerix's common stock. The stock options have a 10-year term and will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the following three years.
The exercise price is set at Chimerix's closing trading price on the grant date. While subject to the terms of Chimerix's 2024 Equity Incentive Plan, these grants were made outside of it. The company, a biopharmaceutical firm, is currently developing dordaviprone (ONC201) for H3 K27M-mutant glioma and conducting Phase 1 dose escalation studies of ONC206.
Chimerix (NASDAQ: CMRX) announced that Chief Scientific Officer Dr. Joshua E. Allen will speak at the Biden Cancer Moonshot Mission Report 2024 forum. The presentation will focus on the program's impact on advancing therapies for brain and rare pediatric cancers, particularly H3 K27M-mutant diffuse glioma.
CEO Mike Andriole highlighted the Cancer Moonshot's achievements in improving health equity in clinical trials and expanding pediatric cancer patient navigation services. Dr. Allen emphasized the program's role as a critical platform for advancing innovation in pediatric and rare cancers.
The company recently submitted a New Drug Application (NDA) for dordaviprone to the FDA, seeking accelerated approval for recurrent H3 K27M-mutant diffuse glioma. With a requested Priority Review, a PDUFA action date could be set for Q3 2025. Dordaviprone has received Rare Pediatric Disease Designation and has applied for a Rare Pediatric Disease Priority Review Voucher.
Chimerix (NASDAQ: CMRX) has submitted a New Drug Application (NDA) to the FDA seeking accelerated approval for dordaviprone, targeting patients with recurrent H3 K27M-mutant diffuse glioma. The company has requested Priority Review, which could lead to a potential PDUFA date in Q3 2025. Dordaviprone has received Rare Pediatric Disease Designation and the company has applied for a Rare Pediatric Disease PRV.
To support the potential launch, Chimerix has secured access to up to $30 million through a Silicon Valley Bank credit facility. The agreement allows for an initial draw of up to $20 million through February 2026, with an additional $10 million available through February 2027, subject to approval. The company has enhanced its commercial capabilities across multiple functions to prepare for potential market launch.
